Drug Profile
Research programme: cytokine-antibody conjugated cancer therapeutics - Teva Pharmaceutical Industries
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cephalon
- Developer Teva Pharmaceutical Industries
- Class Antibodies; Cytokines; Immunotoxins; Interferons
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
- 05 Jan 2011 Preclinical trials in Cancer in Australia (Parenteral)